Global Yeast Infection Treatment Market -2022-2029

Global Yeast Infection Treatment Market -2022-2029

Market Overview

The global yeast infection treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Candidiasis, known as yeast infection, is a common type of fungal infection. Yeast infection can affect any human body region, including the skin, oral cavity, and intestines. Vaginal yeast infection, known as candidal vaginitis or candidal vulvovaginitis, is extremely common and widespread among women (CVV). Candida Albicans is the most usual fungus that causes vaginal yeast infection.

Market Dynamics

Itching, burning, swelling, rashes, and redness are some of the symptoms of a vaginal yeast infection, and the underlying causes are chronic antibiotic use, poor hygiene, lifestyle disease, and weakened immune. These reasons are expected to increase the demand for yeast infection treatment. The rising prevalence of cardiovascular, gastrointestinal, and other disorders is also expected to drive the yeast infection treatment market during the forecast period.

Rise in the prevalence of yeast infections will drive the market growth

The rise in the prevalence of yeast infections, the emergence of new fungal diseases, the increased use of antibiotics, which makes yeast infections resistant to them, and increased research and development on yeast infections are all expected to drive the market throughout the forecast period. According to several clinical research, 75 percent of women will get yeast infection once or twice. Furthermore, vaginal yeast infections are the second-most common cause of abnormal vaginal discharge in the United States.

According to National Center for Biotechnology Institute research, a yeast infection caused 1 billion individuals to suffer from skin, nail, and hair fungal infections in 2017, with 10 million suffering from mucosal candidiasis and 150 million suffering from serious fungal diseases. The rising prevalence of the HIV/AIDS pandemic, chronic obstructive pulmonary disease, asthma, and the rising incidence of malignancies are just a few factors expected to drive the yeast infection treatment market over the projected period.

According to National Center for Biotechnology Institute research, between 30 to 50 percent of women were impacted by vulvovaginal candidiasis at some point in their lives in 2018. In 2018, 40% of women in Germany reported incidences of vulvovaginal candidiasis. Candida species have been identified as the most frequent yeast infection in the Asia Pacific. Candidemia is the most frequent kind of invasive candidiasis in Australia, with an incidence rate of 0.05- 0.36 per 1000 people. All of these data are expected to increase the yeast infection treatment market during the projected period.

Side effects of medications is likely to hamper the market growth

However, side effects of medications, such as nausea, irritation in vagina, burning sensation, a lack of awareness in developing countries limit the growth of the yeast infection treatment industry.

COVID-19 Impact Analysis

In reaction to supply chain disruptions, governments have adopted several initiatives. The European Medicines Agency, for example, has published guidance to pharmaceutical companies regarding the regulatory framework for coping with the issues of this epidemic. These efforts were designed to lessen the outbreak's impact on production and supply.

According to new 2020 reports, around one-third of patients with severe COVID-19 infection require intensive care and maybe fight another deadly infection: Aspergillosis, a terrible fungal infection caused by the Aspergillus fungus. As a result, researchers discovered that people with COVID-19 may be more susceptible to lung infections caused by fungal respiration. As a result, experts are working to conduct additional research in this area. Scientists began diagnosing COVID-19 patients with Mucormycosis during India's second wave of COVID-19 infections. The DCGI withdrew applications for Amphotericin B, which is used to treat mucormycosis, from five fungal medicine companies in May 2021. As a result, while the epidemic scenario is projected to stimulate demand for OTC products in the near term, the drop in the number of pharmaceuticals and drugs for diagnosis and disruptions in the supply chain may cause a temporary setback.

Segment Analysis

The candida albicans segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Candida albicans segment growth is expected to boost over the forecast period, owing to increasing number of patients infected with candidiasis in developing regions. According to the Centers for Disease Control and Prevention (CDC), around 46,000 cases of healthcare-associated invasive candidiasis occur in the United States each year. According to the CDC, the 30-day all-cause (crude) death rate among persons with candidemia is around 30%.

Furthermore, in June 2021, the FDA has approved ibrexafungerp tablets (Brexafemme) as a one-day oral medication for vaginal yeast infections, which affect three out of every four women at some point in their lives. As a result, various market players' number of regulatory authority approvals for products is boosting the market growth.

Geographical Analysis

North America region holds the largest market share of the global yeast infection treatment market

North America dominated the yeast infection treatment market, followed by the Europe market. The rise in yeast infection and the number of occurrences of vaginal infections is a major driver of the market in the region. Furthermore, an increase in the burden of the urological patient population, sophisticated healthcare infrastructure, and advantageous reimbursement situations in the region are just a few of the anticipated to drive the yeast infection treatment market in North America.

According to the Centers for Disease Control and Prevention, vaginal candidiasis is the second-most frequent infection in the United States, with an estimated 1.4 million outpatient visits each year. The yeast infection treatment market in Europe is expected to follow the market in North America, owing to the rising prevalence of yeast infection, increasing cases of vaginal infection in women patients, and the introduction of new treatment options for yeast infections.

The incidence of fungal species infections, such as Candida Auris infections, is at an all-time high, a big worry for European healthcare settings. This fuels the region's desire for yeast infection therapy.

Competitive Landscape

The yeast infection treatment market is a highly competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Basilea Pharmaceutical, Astellas, Paogen Biopharmaceutical, Nov Digm Therapeutics, Bayer, Prestige Consumer, SYNEXIS, Manusaketteva, Pestige Consumer, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the yeast infection treatment market globally. For instance, In January 2020, The US Food and Drug Association has approved a supplemental New Drug Application (sNDA) for the expanded indication of MYCAMINE (micafungin for injection) to treat invasive candidiasis in pediatric patients younger than four months of age.

Prestige Consumer Healthcare

Overview:

Prestige Consumer Healthcare is an American firm that sells branded over-the-counter healthcare and domestic cleaning products to mass merchandisers, drugstores, convenience stores, supermarkets, and online retailers.

Product Portfolio:

Monistat: This drug is used to treat yeast infections in the vaginal area. Tioconazole ointment relieves vaginal burning, itching, and discharge caused by this disorder. This is an azole antifungal drug. It acts by inhibiting the growth of the yeast (fungus) responsible for the illness.

Why Purchase the Report?

Visualize the composition of the global yeast infection treatment market segmentation by pathogen type, infection type,, drug type, route of administration, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global yeast infection treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global yeast infection treatment market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global yeast infection treatment market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 190 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Yeast Infection Treatment Market– By Pathogen Type

Candida Albicans

Candida Glabrata

Candida Rugosa

Others

Global Yeast Infection Treatment Market- By Infection Type

Vaginal Infection

Throat Infection

Skin Infection

Esophagus Infection

Others

Global Yeast Infection Treatment Market- By Drug Type

Polyene

Azole

Others

Global Yeast Infection Treatment Market– By Distribution Channel

Retail Pharmacies

E-Commerce

Hospital Pharmacies

Global Yeast Infection Treatment Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America